Skip to content

Author

H. Döhner

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Cusatuzumab is a monoclonal antibody that binds with high affinity to CD70, a cell surface protein overexpressed on CD34+ acute myeloid leukemia (AML) progenitors and leukemia stem cells. This phase Ib study assessed the safety, tolerability and efficacy of adding cusatuzumab to standard-of-care azacitidine and venetoc...

G. Roboz, Thomas Pabst, A. Aribi et al. · 1 citation
Open access Sep 2026

DDX41 mutations establish a separate entity in acute myeloid leukemia with distinct survival outcomes

Recurrent germline variants in DDX41 represent the most common inherited predisposition to adult myeloid neoplasms, occurring in approximately 3% – 5% of patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). 1,2 Clinically, patients with DDX41 ‐ mutated AML are typically older at diagnosis, pred...

Carolin Seeling, Maral Saadati, D. Späth et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.